MYC and neoplasm: Moreover, with poor prognosis in patients with hepatocellular carcinoma, where it significantly reprograms super-enhancers, it promotes overexpression of the oncogenes associated with super-enhancers, such as MYC, MYCN, and CCND1, and it facilitates tumor progression in vivo and cell proliferation in vitro [99].